The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review

• Published in: JACC CardioOncology Vol. 6; no. 2; pp. 159 - 182
• Main Authors: Dabour, Mohamed S, George, Mina Y, Daniel, Mary R, Blaes, Anne H, Zordoky, Beshay N
• Format: Journal Article
• Language: English
• Published: United States 01-04-2024
• Subjects: cardiotoxicity; cancer; anthracyclines; cardio-oncology; SGLT2 inhibitors
• ISSN: 2666-0873
• DOI: 10.1016/j.jaccao.2024.01.007

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2 diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly heart failure, in patients with and without diabetes. An intriguing research area involves exploring the potential application of SGLT2 inhibitors in cardio-oncology, aiming to mitigate the cardiovascular adverse events associated with anticancer treatments. These inhibitors present a unique dual nature, offering both cardioprotective effects and anticancer properties, conferring a double benefit for cardio-oncology patients. In this review, the authors first examine the established cardioprotective effects of SGLT2 inhibitors in heart failure and subsequently explore the existing body of evidence, including both preclinical and clinical studies, that supports the use of SGLT2 inhibitors in the context of cardio-oncology. The authors further discuss the mechanisms through which SGLT2 inhibitors protect against cardiovascular toxicity secondary to cancer treatment. Finally, they explore the potential anticancer effects of SGLT2 inhibitors along with their proposed mechanisms.